---
title: Merck KGaA vs ProBio
slug_a: merck-kgaa
slug_b: probio
site: cdmo
review_signal_gate: closed
canonical_path: /compare/merck-kgaa/probio
---

# Merck KGaA vs ProBio

Side-by-side profile data from each company listing on this directory.

## Merck KGaA

- Profile: [/companies/merck-kgaa](/companies/merck-kgaa)

Merck KGaA — Recent coverage reports that Merck KGaA plans to sell its life science CDMO business to Lonza. The same coverage describes a new €300 million bioprocessing center in Daejeon, South Korea.

Services: 0. Modalities: 0. Indications: 0. Locations: 1. Certifications: 0. The strongest documented coverage currently appears in locations (1).

### Services

- Data not yet provided.

### Modalities

- Data not yet provided.

### Development capabilities

- Data not yet provided.

### Manufacturing capabilities

- Data not yet provided.

## ProBio

- Profile: [/companies/probio](/companies/probio)

ProBio — ProBio is a leading global CDMO subsidiary of GenScript Biotech Corporation, providing end-to-end services for biologics and cell & gene therapy (CGT) from drug discovery through commercialization.

Services: 7. Modalities: 7. Indications: 1. Locations: 6. Certifications: 3. The strongest documented coverage currently appears in services (7).

### Services

- Protein Engineering
- In Vitro Pharmacology
- Bioanalysis
- Immunogenicity Assays (ADA / NAb)
- Flow Cytometry Services
- Analytical Method Development & Validation
- ICH Stability Studies

### Modalities

- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- mRNA
- Cell Therapy
- Gene Therapy
- Vaccine
- AAV / Viral Vector Platform

### Development capabilities

- Data not yet provided.

### Manufacturing capabilities

- Data not yet provided.